MERCK & CO. INC. (MRK)

Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer

Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Surendralal Karsanbhai Elected to Merck Board of Directors

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities

NYSE:MRK appears to be flying under the radar despite its strong fundamentals.

In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.

J&J, Merck Cut Jobs in China as Local Competition Takes Toll

Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing’s campaign to drive down medical costs.

Merck Announces First-Quarter 2025 Dividend

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

Notable Thursday Option Activity: MRK, SONO, AA

MRK July 2025 Options Begin Trading

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.

Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

Merck to Participate in the Jefferies London Healthcare Conference

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.

See Which Of The Latest 13F Filers Holds Merck

KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial

Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024

3 Stocks Poised for a Breakout

All 3 stocks are high on my watchlist.

2 Hot Biopharma Stocks to Buy and Hold for 5 Years

If you're patient, these businesses have a lot of promising projects in the works.

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

These stocks have seen better days but investors shouldn't count them out in the long run.

Merck to Participate in the UBS Global Healthcare Conference

2 Magnificent Stocks to Buy That Are Near 52-Week Lows

These stocks near 52-week lows could be ready to rebound.

Why NYSE:MRK is a Top Pick for Dividend Investors.

Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.